-
Je něco špatně v tomto záznamu ?
Body composition changes during and after curative chemotherapy in patients with testicular cancer
O. Semerad, T. Buchler, J. Vejmelka, A. Rozsypalova, J. Tomesova, P. Kohout
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2001
Free Medical Journals
od 1998
Medline Complete (EBSCOhost)
od 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
PubMed
33325458
DOI
10.5507/bp.2020.058
Knihovny.cz E-zdroje
- MeSH
- cisplatina terapeutické užití MeSH
- elektrická impedance MeSH
- index tělesné hmotnosti MeSH
- lidé MeSH
- složení těla fyziologie MeSH
- testikulární nádory * farmakoterapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Testicular cancer is associated with excellent prognosis and cure is achieved in most patients with advanced cancer treated with cisplatin-based chemotherapy. However, testicular cancer survivors are at increased risk of accelerated atherosclerosis, which significantly contributes to their late morbidity and mortality. Atherosclerosis is associated with a higher proportion of fat mass and especially with increased amount of visceral fat. We explored the effects of cisplatin-based chemotherapy on body composition during and after the treatment. PATIENTS AND METHODS: We studied 30 testicular cancer patients before chemotherapy, after the second cycle of chemotherapy and three months after the end of chemotherapy. Body composition parameters were evaluated using bioelectrical impedance analysis (BIA). RESULTS: Three months after the end of chemotherapy the fat mass had increased from 22.04±7.15% to 23.92±7.33% (P=0.026) and visceral fat volume had increased by 17% from 2.36±1.75l to 2.77±1.94l (P=0.013). In the whole sample there was a decrease in muscle mass after the second cycle of chemotherapy (-1.33 ± 2 kg on average; P=0.005). The changes in body composition varied according to distinct baseline fat mass. CONCLUSION: Cisplatin-based chemotherapy was associated with increase of fat mass, visceral fat, and body mass index. We also observed decrease in muscle mass and total body water. Our results suggest that BIA could help to target preventative measures to avert the acceleration of atherosclerosis in patients treated with cisplatin-based chemotherapy.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22009430
- 003
- CZ-PrNML
- 005
- 20220721082502.0
- 007
- ta
- 008
- 220419s2022 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2020.058 $2 doi
- 035 __
- $a (PubMed)33325458
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Semerád, Otakar $7 xx0274857 $u Department of Internal Medicine, Third Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
- 245 10
- $a Body composition changes during and after curative chemotherapy in patients with testicular cancer / $c O. Semerad, T. Buchler, J. Vejmelka, A. Rozsypalova, J. Tomesova, P. Kohout
- 504 __
- $a Literatura
- 520 9_
- $a BACKGROUND: Testicular cancer is associated with excellent prognosis and cure is achieved in most patients with advanced cancer treated with cisplatin-based chemotherapy. However, testicular cancer survivors are at increased risk of accelerated atherosclerosis, which significantly contributes to their late morbidity and mortality. Atherosclerosis is associated with a higher proportion of fat mass and especially with increased amount of visceral fat. We explored the effects of cisplatin-based chemotherapy on body composition during and after the treatment. PATIENTS AND METHODS: We studied 30 testicular cancer patients before chemotherapy, after the second cycle of chemotherapy and three months after the end of chemotherapy. Body composition parameters were evaluated using bioelectrical impedance analysis (BIA). RESULTS: Three months after the end of chemotherapy the fat mass had increased from 22.04±7.15% to 23.92±7.33% (P=0.026) and visceral fat volume had increased by 17% from 2.36±1.75l to 2.77±1.94l (P=0.013). In the whole sample there was a decrease in muscle mass after the second cycle of chemotherapy (-1.33 ± 2 kg on average; P=0.005). The changes in body composition varied according to distinct baseline fat mass. CONCLUSION: Cisplatin-based chemotherapy was associated with increase of fat mass, visceral fat, and body mass index. We also observed decrease in muscle mass and total body water. Our results suggest that BIA could help to target preventative measures to avert the acceleration of atherosclerosis in patients treated with cisplatin-based chemotherapy.
- 650 _2
- $a složení těla $x fyziologie $7 D001823
- 650 _2
- $a index tělesné hmotnosti $7 D015992
- 650 _2
- $a cisplatina $x terapeutické užití $7 D002945
- 650 _2
- $a elektrická impedance $7 D017097
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a testikulární nádory $x farmakoterapie $7 D013736
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Büchler, Tomáš, $d 1974- $7 xx0096851 $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
- 700 1_
- $a Vejmelka, Jiří $7 mzk2017961281 $u Department of Internal Medicine, Third Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
- 700 1_
- $a Rozsypalová, Aneta $7 xx0224255 $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
- 700 1_
- $a Tomešová, Jitka $7 xx0071680 $u Nutrition Centre, Thomayer Hospital, Prague, Czech Republic
- 700 1_
- $a Kohout, Pavel, $d 1962- $7 xx0000566 $u Department of Internal Medicine, Third Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 166, č. 1 (2022), s. 91-96
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33325458 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20220419 $b ABA008
- 991 __
- $a 20220721082456 $b ABA008
- 999 __
- $a ok $b bmc $g 1815561 $s 1160628
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 166 $c 1 $d 91-96 $e 20201215 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20220419